Initial Treatment for Non-Erosive Esophagitis

First-Line Pharmacologic Approach

The American Gastroenterological Association recommends starting with a single-dose proton pump inhibitor (PPI) taken once daily, 30-60 minutes before the first meal of the day, for 4-8 weeks, then weaning to the lowest effective dose or on-demand therapy if symptoms are controlled 1
The American College of Gastroenterology suggests beginning with standard-dose PPI once daily (e.g., omeprazole 20 mg, lansoprazole 30 mg, esomeprazole 40 mg, pantoprazole 40 mg, or rabeprazole 20 mg) taken 30-60 minutes before breakfast for optimal acid suppression 1
PPIs must be taken before meals to coincide with postprandial peak in active proton pumps for maximum efficacy, as recommended by the American Gastroenterological Association 2
Patients with typical reflux symptoms (heartburn, acid regurgitation) without alarm symptoms should have their response evaluated after an initial 4-8 week trial period, according to the American College of Gastroenterology 1

The American Gastroenterological Association notes that non-erosive disease allows for de-escalation: once symptoms are controlled, patients can be weaned to the lowest effective dose and potentially transition to on-demand therapy with H2 blockers or antacids 3, 4, 1
In contrast to erosive esophagitis, which requires continuous daily PPI therapy indefinitely to prevent recurrence, non-erosive esophagitis can be managed with less intensive regimens, as recommended by the American College of Gastroenterology 5

The American Gastroenterological Association recommends avoiding recumbency for 2-3 hours after meals to reduce nocturnal reflux episodes, and elevating the head of the bed and using left lateral decubitus sleeping position to improve nocturnal esophageal acid exposure 6
Weight loss is recommended if overweight or obese, as obesity is significantly associated with reflux symptoms, according to the American College of Gastroenterology 6
Avoiding individual trigger foods on a patient-by-patient basis rather than blanket dietary restrictions is suggested, as data on specific food avoidance are limited, as noted by the American Gastroenterological Association 6
Limiting fat intake to less than 45 grams per day and avoiding late evening meals is recommended, according to the American College of Gastroenterology 6, 2

The American Gastroenterological Association recommends weaning to the lowest effective dose that maintains symptom control for responders after an initial 4-8 week trial 3, 1
On-demand therapy with PPIs, H2 blockers, or antacids is a reasonable strategy specifically for non-erosive disease, if symptoms remain controlled, as suggested by the American College of Gastroenterology 3, 4, 7
Diagnostic testing with endoscopy and prolonged wireless pH monitoring off PPI therapy should be considered for non-responders or incomplete responders to characterize disease severity and rule out alternative diagnoses, according to the American Gastroenterological Association 3, 1

The American Gastroenterological Association emphasizes the safety of PPIs when discussing treatment options with patients, as concerns about long-term PPI use are often overblown 8
Providing standardized educational material on GERD mechanisms, lifestyle modifications, and the brain-gut axis relationship is recommended, according to the American College of Gastroenterology 8
The main identifiable risk of reducing or discontinuing PPI therapy is increased symptom burden rather than disease progression, as there are no high-quality data suggesting that intermittent symptoms or discontinuing therapy in non-erosive disease is harmful, as noted by the American Gastroenterological Association 7